Patient-matched organoid systems for studying cancer
WO2021081032A1
Compositions comprising modified smarcb1 and uses thereof
WO2021077018A1
Compositions and methods for modulating innate immune signaling pathways
WO2021072211A1
Compositions and methods for treating cytotoxic t cell resistant tumors
WO2021071922A1
A pyrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases
WO2021071919A1
Hck as a therapeutic target in myd88 mutated diseases
US2021102166A1
Compositions and methods for modulating and detecting tissue specific th17 cell pathogenicity
US2021102168A1
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
WO2021067682A1
Tricyclic kinase inhibitors and uses thereof
WO2021067800A1
Anti-kir3dl3 antibodies and uses thereof
WO2021067546A1
Immunomodulatory imide drugs as zeta-chain-associated protein kinase 70 (zap70) agonists and uses thereof
WO2021061990A1
Compositions and methods for treatment of a poor prognosis subtype of colorectal cancer
WO2021061894A1
Erk5 degraders as therapeutics in cancer and inflammatory diseases
US2021087638A1
Next-generation sequencing assay for genomic characterization and minimal residual disease detection in the bone marrow, peripheral blood, and urine of multiple myeloma and smoldering myeloma patients
WO2021061736A1
Methods of high-throughput identification of t cell epitopes by capturing cytokines on the surface of antigen-presenting cells
WO2021055530A1
Protein tag to induce ligand dependent degradation of protein/protein-fusions
WO2021050832A2
Methods for treating cancer using serial administration of e3 ubiquitin ligase degraders
